A comprehensive single-center retrospective analysis incorporating data from multiple trials confirmed that diminished or absent CD19 expression represents a major contributor to treatment failure in pediatric B-ALL (30). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.